View Post

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Jessica Skarzynski From: For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated promising activity in patients with recurrent ovarian cancer or advanced breast cancer. In the JAMA Oncology study, the …